Investment Rating - The report initiates coverage with a "Buy" rating for Jacobiopharma-B (1167.HK) [1]. Core Views - Jacobiopharma focuses on innovative drug development targeting difficult-to-drug targets, with a strong pipeline and comprehensive patent strategy to build competitive barriers [6][7]. - The company has established strategic partnerships to enhance drug development and commercialization, particularly with AbbVie and Elysium [6][20]. - The KRAS G12C inhibitor, Goleirase, has been approved for marketing in China, and the company is actively pursuing further clinical trials and partnerships to maximize its market potential [6][39]. Summary by Sections 1. Focus on Difficult-to-Drug Targets - Jacobiopharma aims to develop globally innovative drugs targeting difficult-to-drug cancer targets, with a management team experienced in drug development and international collaboration [13][17]. - The company's revenue primarily comes from licensing agreements, with stable funding supporting long-term development [20][24]. - The company has a solid cash position of 1.34 billion yuan as of June 30, 2025, which supports its future expenditures [20][24]. 2. Coverage of Different KRAS Mutations - KRAS plays a critical role in cell growth and survival signaling, and its mutations are linked to cancer progression [30]. - The KRAS G12C inhibitor, Goleirase, has been approved in China, and the company has formed a strategic partnership with Elysium for its commercialization [36][39]. - The company is also developing a pan-KRAS inhibitor, JAB-23E73, which is expected to provide broader coverage of KRAS mutations and address resistance issues [46]. 3. Key Assumptions and Investment Rating - The report projects revenues of 0.52 billion yuan in 2025, 0.74 billion yuan in 2026, and 1.15 billion yuan in 2027, reflecting the company's growth trajectory [8][12]. - The company is expected to continue advancing its research and development projects while maintaining controlled operating expenses [6][20].

Investment Rating - The report maintains a "Buy" rating for JD Health (06618) [4][10] Core Insights - JD Health's Q3 2025 financial results exceeded expectations, with revenue of 17.12 billion (up 28.7%) and adjusted net profit of 1.90 billion (up 42.4%) [8][9] - The company is expected to benefit from strong growth in drug sales, increased advertising revenue, and enhanced AI capabilities [9][10] - The report projects revenue growth for 2025-2027, with estimates of 70.95 billion, 81.99 billion, and 93.49 billion respectively [6][10] Financial Data and Profit Forecast - Revenue and profit forecasts for JD Health are as follows: - 2023: Revenue 53.53 billion, Net Profit 2.14 billion - 2024: Revenue 58.16 billion, Net Profit 4.16 billion - 2025E: Revenue 70.95 billion, Net Profit 4.74 billion - 2026E: Revenue 81.99 billion, Net Profit 5.66 billion - 2027E: Revenue 93.49 billion, Net Profit 6.76 billion [6][12]

公司深度研究 | 十月稻田 厨房主食中的新消费 十月稻田（09676.HK）首次覆盖报告 所处行业空间较大且持续增长，集中度有望提升。公司所处的厨房主食行业 为万亿以上规模的大行业，且近年来持续增长，公司重点布局的大米、玉米 等品类均为千亿级大行业且增长势头明显。行业中的预包装产品、优质产品 有较好的增长且增长势头显著快于行业整体。当前该行业市场集中度很低， 但预包装产品、优质产品、东北大米产品等的集中度显著高于行业整体，预 计随着上述关键品类的快速增长，行业集中度有望提升，公司作为重要的行 业龙头之一有望显著获益。 产品矩阵丰富，多元化渠道覆盖全国。公司旗舰品牌十月稻田、柴火大院已 在京东等平台复购率高于行业整体，并依托多品牌构建了全面且互补的产品 矩阵，满足不同类别消费者的个性化需求。公司建立多元化、涵盖线上线下 的销售网络，在新渠道保持领先，在线下渠道和经销商建立了深厚的合作关 系。公司通过在核心产区的五大生产基地，结合遍布多区域的区域仓，形成 辐射全国多数区域的供应链能力。 投资建议：我们预测 25-27 年公司营收分别为 69.94 亿元/84.35 亿元/99.39 亿元，同比+22%/+21%/ ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 286.9, representing a potential upside of 32.0% from the current price of HKD 217.4 [1][5][15]. Core Insights - The report emphasizes that the company is not solely reliant on the popularity of its Labubu IP, but rather operates as a platform for creating and commercializing multiple IPs. The ability to launch new successful IPs is seen as a key competitive advantage [5]. - Recent sales trends in the U.S. market have shown a recovery, with expectations for continued growth during the holiday season. The report suggests that the recent slowdown in sales was largely due to pre-sales in previous months [5]. - The company has significant growth potential in the North American and European markets, which currently represent a small portion of total revenue. The report highlights the potential for expansion through physical retail stores in these regions [5]. - The current valuation is considered attractive, with a P/E ratio of 15 times the estimated earnings for 2026, indicating high value for investors [5]. Financial Performance and Projections - The company is projected to achieve substantial revenue growth, with estimated revenues of RMB 38,003 million in 2025, reflecting a year-on-year increase of 191.5% [7][10]. - Net profit is expected to reach RMB 12,920 million in 2025, representing a significant increase of 313.4% compared to the previous year [7][10]. - The report outlines a steady improvement in profit margins, with gross profit margins projected to rise to 70.8% by 2025 [10][11]. Market Performance - The company's stock has experienced volatility, but recent data suggests a recovery in market sentiment, with short-selling activity decreasing [5]. - The report notes that the company's sales in the domestic market have shown impressive growth, with online sales increasing by 212% in the first half of 2025 [11]. Regional Revenue Breakdown - In the first half of 2025, the company reported a 440% increase in overseas revenue, with North America showing a staggering growth rate of 1,142% [11]. - The report indicates that the company has only a limited number of retail stores in North America and Europe, suggesting significant room for growth in these markets [5].

Investment Rating - The investment rating for the company is "Recommended" [1] Core Views - The company reported a narrowing loss in Q3 2025, with a revenue of 20.38 billion yuan, representing a year-on-year increase of 101.8% and a quarter-on-quarter increase of 11.5%. The net profit attributable to shareholders was -0.38 billion yuan, narrowing by 78.9% year-on-year and 20.3% quarter-on-quarter [3][6] - The company achieved a vehicle delivery volume of 116,000 units in Q3, a year-on-year increase of 149.3% and a quarter-on-quarter increase of 12.4%. The automotive business revenue reached 18.05 billion yuan, with a year-on-year increase of 105.3% and a quarter-on-quarter increase of 6.9% [6] - The company is expanding its collaboration with Volkswagen, which has become a strategic partner for the second-generation VLA model, indicating potential growth in revenue from R&D services [6][7] - The launch of the Kunpeng Super Range Extender is expected to open new growth opportunities in the new energy vehicle sector [6][7] - The second-generation VLA model was released, which enhances the company's capabilities in physical AI, with plans to launch three Robotaxi models in 2026 [7] Financial Summary - The company’s projected revenues for 2025 to 2027 are 76.93 billion yuan, 117.47 billion yuan, and 144.84 billion yuan, respectively, with year-on-year growth rates of 88.2%, 52.7%, and 23.3% [5][10] - The net profit is expected to improve from -1.4 billion yuan in 2025 to 4.5 billion yuan in 2027, reflecting a significant turnaround [5][10] - The gross margin for the automotive business is projected to increase from 18.2% in 2025 to 20.5% in 2027, indicating improved profitability [5][10] Delivery and Revenue Guidance - The company has provided a Q4 delivery guidance of 125,000 to 132,000 units, corresponding to a revenue guidance of 21.5 billion to 23 billion yuan [6] - In October, the company delivered 42,013 vehicles, with an expected average monthly delivery of 41,000 to 45,000 units for November and December [6]

Investment Rating - The report maintains a "Buy" rating for the company [6]. Core Insights - The company reported a significant revenue increase of 101.8% year-on-year for Q3 2025, reaching 20.38 billion yuan, with automotive business revenue growing by 105.3% [3][4]. - The gross margin for the automotive business improved to 13.1%, driven by a decrease in costs, although it saw a slight decline from the previous quarter due to product updates [4]. - The company is optimistic about future performance, projecting Q4 2025 automotive sales between 125,000 and 132,000 units, representing a year-on-year increase of 36.6% to 44.3% [5]. Revenue and Profitability - Q3 2025 revenue was 20.38 billion yuan, with automotive revenue at 18.05 billion yuan [3][4]. - The total gross profit for Q3 2025 was 4.1 billion yuan, with a gross margin of 20.1% [4]. - Non-GAAP net profit for Q3 2025 was a loss of 150 million yuan, marking a significant reduction in losses of 90.1% year-on-year [3]. Cost Management - R&D expenses for Q3 2025 were 2.43 billion yuan, up 48.7% year-on-year, reflecting increased costs associated with new product launches [5]. - Selling and administrative expenses were 2.49 billion yuan, a 52.6% increase year-on-year, primarily due to higher sales commissions and marketing costs [5]. Future Outlook - The company forecasts revenues of 78.13 billion yuan in 2025, 110.81 billion yuan in 2026, and 131.64 billion yuan in 2027, with expected net profits turning positive in 2026 [8][9]. - The report highlights the company's strategic focus on intelligent products, including the launch of Robotaxi and the new generation of IRON humanoid robots, which are expected to enhance its market position [7][8].

Investment Rating - The report maintains an "OUTPERFORM" rating for XPeng Motors, with a current price of HK$96.00 and a target price of HK$96.23 [2][3]. Core Insights - XPeng Motors is experiencing a recovery in earnings, with technology services emerging as a new growth driver. The company reported Q3 2025 revenue of Rmb20.38 billion, slightly below market expectations, but up 102% year-over-year and 12% quarter-over-quarter. The net loss narrowed to Rmb380 million, improving 79% year-over-year and 20% quarter-over-quarter. The gross margin rose to 20.1%, with service and other margins significantly contributing to gross-margin expansion, particularly from technical R&D services to OEMs like Volkswagen [3][10]. Financial Performance Summary - Revenue projections for XPeng are Rmb40.87 billion for 2024, Rmb78.46 billion for 2025, and Rmb112.03 billion for 2026, reflecting growth rates of 33%, 92%, and 43% respectively. The net profit is expected to turn positive in 2026, with a projected net profit of Rmb1.12 billion and a diluted EPS of Rmb0.59 [9][10]. - The gross profit margin is expected to improve from 14.3% in 2024 to 19.0% in 2027, indicating a positive trend in profitability [9]. Strategic Developments - The company plans to launch its Robotaxi fleet next year, leveraging in-house technology development to reduce costs and improve operational efficiency. Initial commercialization will focus on system robustness and regulatory compliance, with plans to expand to more cities [4][11]. - XPeng is also advancing its humanoid robot production, targeting mass production of its eighth-generation model and aiming for annual deliveries of 1 million units by 2030. The cost structure is expected to improve significantly, with software accounting for over 50% of total costs [12][13]. Market Expansion - Overseas markets are projected to be a significant growth driver in 2026, with a strategy that includes passenger vehicles, Robotaxi, and humanoid robots. The company plans to launch multiple BEV/EREV models, with at least three planned for export [13].

Investment Rating - The investment rating for Geely Automobile is "Buy" (maintained) [1] Core Views - The Q3 performance of Geely Automobile met expectations, with total revenue of 89.19 billion yuan, representing a year-on-year increase of 26.5% and a quarter-on-quarter increase of 14.7%. The net profit attributable to the parent company was 3.82 billion yuan, showing a year-on-year increase of 59.3% and a quarter-on-quarter increase of 5.6% [2] - The company achieved total sales of 761,000 units in Q3, with a year-on-year increase of 42.5% and a quarter-on-quarter increase of 7.9%. The average selling price (ASP) per vehicle was 117,000 yuan, reflecting a year-on-year decline of 11.2% but a quarter-on-quarter increase of 6.3% [2] - The gross margin for Q3 was 16.6%, showing a year-on-year improvement due to scale effects and product mix enhancement, despite a quarter-on-quarter decline [2] - The company has adjusted its net profit forecast for 2025 to 18.1 billion yuan (previously 15 billion yuan) due to strong sales performance in the first three quarters and the successful launch of new models [2] Summary by Sections Revenue and Profitability - Total revenue for 2023 is projected at 179.204 billion yuan, with a year-on-year growth of 21.11%. For 2024, revenue is expected to reach 240.194 billion yuan, growing by 34.03% [1] - The net profit attributable to the parent company for 2023 is estimated at 5.308 billion yuan, with a year-on-year increase of 0.91%. The forecast for 2024 is 16.632 billion yuan, reflecting a significant growth of 213.32% [1] Earnings Per Share (EPS) and Valuation - The latest diluted EPS for 2023 is projected at 0.52 yuan per share, with a forecast of 1.64 yuan for 2024 and 1.79 yuan for 2025 [1] - The price-to-earnings (P/E) ratio is expected to be 29.84 for 2023, decreasing to 9.52 for 2024 and further to 8.76 for 2025 [1] Financial Metrics - The company’s total assets are projected to reach 325.928 billion yuan by 2025, with a debt-to-asset ratio of 66.04% [9] - The cash flow from operating activities for 2025 is expected to be 29.426 billion yuan, indicating a healthy cash generation capability [9]

Investment Rating - The report assigns an "Outperform" rating to the company for the first time, with a target price range of HKD 31.00 to HKD 36.50 per share [5]. Core Insights - The company is a leading Hong Kong jewelry brand that has shown operational efficiency and positive same-store sales growth despite facing challenges from rising gold prices and changing consumer environments. The company achieved a revenue of HKD 133.41 billion in FY2025, with 39.5% from mainland China and 60.5% from Hong Kong, Macau, and overseas markets [1][3]. - The jewelry consumption logic has shifted towards a dual value proposition of "fashion + value preservation," driven by innovative design and craftsmanship, which has enhanced the appeal of gold jewelry. This trend is expected to support margin recovery and drive stock price appreciation [1][3]. - The company is actively developing differentiated products that meet market demands, with a focus on optimizing sales capabilities in domestic stores and expanding overseas [2][3]. Summary by Sections Financial Performance - The company reported a revenue of HKD 133.41 billion for FY2025, a decrease of 12.95% year-on-year, and a net profit of HKD 1.1 billion, down 37.77% year-on-year. Adjusting for gold hedging losses and one-time gains from acquisitions, the decline in profit was narrowed to 6.3% [13][31]. - The forecast for net profit for FY2026 to FY2028 is projected at HKD 15.01 billion, HKD 17.87 billion, and HKD 20.28 billion, representing year-on-year growth rates of 36.48%, 19.08%, and 13.44% respectively [3][4]. Market Trends - The jewelry market is experiencing a shift towards gold products, which are expected to account for 80% of sales by 2024. The demand for gold jewelry is being driven by its perceived value preservation attributes amid rising gold prices [48][53]. - The company plans to open 50 new overseas stores in the coming years, capitalizing on the growing demand from overseas Chinese consumers and the global trend of seeking value-preserving investments [66][68]. Product and Channel Strategy - The company is focusing on product innovation and channel optimization, with a significant portion of revenue coming from self-operated and e-commerce retail, which accounted for 82.7% of total revenue in FY2025 [20][23]. - The introduction of high-margin fixed-price gold products has contributed to margin recovery, with the gross margin for gold and platinum products increasing to 26.35% in FY2025 [31][60]. Competitive Landscape - The jewelry industry is characterized by intense competition, with major players like Chow Tai Fook and Lao Feng Xiang dominating the market. The company holds a market share of 0.7%, ranking tenth among competitors [73].

Investment Rating - The report maintains a "Strong Buy" investment rating for Tencent Music [2][5] Core Insights - The company achieved total revenue of 8.46 billion RMB in Q3 2025, representing a year-on-year growth of 20.6%, with adjusted net profit increasing by 32.6% to 2.41 billion RMB [1][5] - Online music revenue continues to grow steadily, with a 27.2% year-on-year increase to 6.97 billion RMB, driven by subscription and advertising services [5][6] - The company is actively expanding into the fan economy and concert business, enhancing its competitive advantages through collaborations and content diversification [5][6] Financial Performance - Revenue and profit growth are supported by effective cost control, with gross margin improving from 42.6% in Q3 2024 to 43.5% in Q3 2025 [5][6] - The online music subscription revenue reached 4.5 billion RMB, up 17.2% year-on-year, driven by an increase in ARPPU from 10.8 RMB to 11.9 RMB [5][6] - The company expects revenues to reach 32.66 billion RMB, 36.98 billion RMB, and 41.30 billion RMB for the years 2025, 2026, and 2027 respectively, with adjusted net profits projected at 9.60 billion RMB, 10.85 billion RMB, and 12.18 billion RMB [6][8] Market Position and Strategy - Tencent Music holds a strong position in content copyright, with a focus on enhancing user willingness to pay and optimizing membership benefits [5][6] - The company is expanding its concert business, having successfully hosted multiple performances in various cities, attracting over 150,000 attendees [5][6] - The introduction of interactive fan communities and exclusive artist-related benefits is expected to drive further growth in subscription rates and user engagement [5][6]